Jury out on UK gene screening and prenatal testing:
This article was originally published in Clinica
Executive Summary
The degree of current and prospective growth in the use of prenatal genetic testing has led the UK's Human Genetics Commission (HGC) to conclude that further consideration is needed to best regulate the technology. In a milestone report, published last week, the commission said it would also monitor developments in national screening programmes. The 180-page report, "Inside Information - Balancing interests in the use of personal genetic data", puts the human subject at the top of the agenda. It is evidence of the growing awareness in the medical and clinical research communities of the high degree of sensitivity surrounding genetics, and the realisation that scientific progress involving the technology is inextricably dependent on the public's confidence in the system that regulates it. The HGC makes a range of recommendations concerning the need to adapt UK primary and secondary legislation to tighten this, and for the users of genetic information to become more closely involved with the scientific community.
You may also be interested in...
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.